SEC Form 4 · accession 0001144204-15-028871
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Gedeon Teper
Officer — CEO · Director · 10% Owner
Period of report
May 6, 2015
Accepted (ET)
May 8, 2015 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $1.87 | May 6, 2015 | A | 250,000 | A | — | May 6, 2025 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1These stock options shall vest upon the Issuer's achievement of certain operation, financing and partnership objectives.